News › Clinical Practice, Industry News, Patient Care

Comparing Neurotoxins

December 10, 2019

When it comes to smoothing wrinkles and minimizing signs of aging, injectable neurotoxins remain one of the most popular options. According to the American Society of Plastic Surgeons, 7.44 million botulinum toxin type A procedures were performed in 2018, which is up 3 percent from the previous year.
Although the original neurotoxin, Allergan’s Botox, was approved in 2002, other brands and formulas followed. Dysport (Galderma) was approved in 2009, Xeomin (Merz Aesthetic) in 2010 and Jeuveau (Evolus) in 2019. While differences in molecular weight, drug medium and complexing proteins mean these brands are not interchangeable, they do all work in a similar way.Read more at MedEsthetics >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Merz Aesthetics’ Radiesse Receives FDA Approval for Décolleté Wrinkles
    • New Book “Get Found, Get Booked” Reveals a Smarter, Ethical Approach to Marketing for Med Spas and Wellness Practices
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available